Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy.
Here we report a successful use of a non-replicating adenovirus expressing the wild-type human beta2m gene in recovery of normal human leucocyte antigen (HLA) class I expression in beta2m-null cancer cells. Total loss of HLA class I expression in these cell lines is caused by a mutation in beta2m gene and a loss of heterozygosity in chromosome 15 carrying another copy of that gene. Normal HLA class I expression on the tumour cell surface is critical for the successful outcome of cancer immunotherapy as T cells can only recognize tumour-derived peptides in a complex with self-HLA class I molecules. In this report we characterize the newly generated adenoviral vector AdCMVbeta2m and demonstrate an efficient beta2m gene transfer in tumour cell lines of different histological origin, including melanoma, prostate and colorectal carcinoma. The beta2m re-expression lasted for an extended period of time both in vitro and in vivo in human tumour xenograft transplants. We propose that in a subset of cancer patients with structural defect in beta2m gene or chromosome 15, the adenoviral-mediated recovery (or even increase) of HLA class I expression on tumour cells in combination with vaccination or adoptive T-cell therapy can provide a complementary approach to improve the clinical efficacy of cancer immunotherapy.
del Campo
A B
AB
Departamento de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada.
Aptsiauri
N
N
Méndez
R
R
Zinchenko
S
S
Vales
A
A
Paschen
A
A
Ward
S
S
Ruiz-Cabello
F
F
González-Aseguinolaza
G
G
Garrido
F
F
D000818:Animals; D002460:Cell Line; D045744:Cell Line, Tumor; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays; D001613:beta 2-Microglobulin / Q000235:genetics*
D015395:Histocompatibility Antigens Class I; D001613:beta 2-Microglobulin